Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors
Ghada M. H. Abdel-Salam, Susanne Hellmuth, Elise Gradhand, Stephan Käseberg, Jennifer Winter, Ann-Sophie Pabst, Maha M. Eid, Holger Thiele, Peter Nürnberg, Birgit S. Budde, Mohammad Reza Toliat, Ines B. Brecht, Christopher Schroeder, Axel Gschwind, Stephan Ossowski, Friederike Häuser, Heidi Rossmann, Mohamed S. Abdel-Hamid, Ibrahim Hegazy, Ahmed G. Mohamed, Dominik T. Schneider, Aida Bertoli-Avella, Peter Bauer, Jillian N. Pearring, Rolph Pfundt, Alexander Hoischen, Christian Gilissen, Dennis Strand, Ulrich Zechner, Soha A. Tashkandi, Eissa A. Faqeih, Olaf Stemmann, Susanne Strand, Hanno J. Bolz
Ghada M. H. Abdel-Salam, Susanne Hellmuth, Elise Gradhand, Stephan Käseberg, Jennifer Winter, Ann-Sophie Pabst, Maha M. Eid, Holger Thiele, Peter Nürnberg, Birgit S. Budde, Mohammad Reza Toliat, Ines B. Brecht, Christopher Schroeder, Axel Gschwind, Stephan Ossowski, Friederike Häuser, Heidi Rossmann, Mohamed S. Abdel-Hamid, Ibrahim Hegazy, Ahmed G. Mohamed, Dominik T. Schneider, Aida Bertoli-Avella, Peter Bauer, Jillian N. Pearring, Rolph Pfundt, Alexander Hoischen, Christian Gilissen, Dennis Strand, Ulrich Zechner, Soha A. Tashkandi, Eissa A. Faqeih, Olaf Stemmann, Susanne Strand, Hanno J. Bolz
View: Text | PDF
Research Article Genetics Oncology

Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors

  • Text
  • PDF
Abstract

MAD2L1BP-encoded p31comet mediates Trip13-dependent disassembly of Mad2- and Rev7-containing complexes and, through this antagonism, promotes timely spindle assembly checkpoint (SAC) silencing, faithful chromosome segregation, insulin signaling, and homology-directed repair (HDR) of DNA double-strand breaks. We identified a homozygous MAD2L1BP nonsense variant, R253*, in 2 siblings with microcephaly, epileptic encephalopathy, and juvenile granulosa cell tumors of ovary and testis. Patient-derived cells exhibited high-grade mosaic variegated aneuploidy, slowed-down proliferation, and instability of truncated p31comet mRNA and protein. Corresponding recombinant p31comet was defective in Trip13, Mad2, and Rev7 binding and unable to support SAC silencing or HDR. Furthermore, C-terminal truncation abrogated an identified interaction of p31comet with tp53. Another homozygous truncation, R227*, detected in an early-deceased patient with low-level aneuploidy, severe epileptic encephalopathy, and frequent blood glucose elevations, likely corresponds to complete loss of function, as in Mad2l1bp–/– mice. Thus, human mutations of p31comet are linked to aneuploidy and tumor predisposition.

Authors

Ghada M. H. Abdel-Salam, Susanne Hellmuth, Elise Gradhand, Stephan Käseberg, Jennifer Winter, Ann-Sophie Pabst, Maha M. Eid, Holger Thiele, Peter Nürnberg, Birgit S. Budde, Mohammad Reza Toliat, Ines B. Brecht, Christopher Schroeder, Axel Gschwind, Stephan Ossowski, Friederike Häuser, Heidi Rossmann, Mohamed S. Abdel-Hamid, Ibrahim Hegazy, Ahmed G. Mohamed, Dominik T. Schneider, Aida Bertoli-Avella, Peter Bauer, Jillian N. Pearring, Rolph Pfundt, Alexander Hoischen, Christian Gilissen, Dennis Strand, Ulrich Zechner, Soha A. Tashkandi, Eissa A. Faqeih, Olaf Stemmann, Susanne Strand, Hanno J. Bolz

×

Figure 6

Comparison of p31comet-WT and -ΔC in isogenic cell lines.

Options: View larger image (or click on image) Download as PowerPoint
Comparison of p31comet-WT and -ΔC in isogenic cell lines.
(A) C-terminal...
(A) C-terminally truncated p31comet cannot associate with Trip13 but retains weak Mad2 binding. Transiently transfected HEK293T cells expressing the indicated FLAG-tagged p31comet variants were Taxol arrested and then subjected to anti-FLAG immunoprecipitation, followed by Western analysis using the indicated antibodies. WT, wild-type (isoform 2, NP_055443.1); PK, Trip13 binding-deficient p31-P228A,K229A; ΔC, amino acids 253–274 deleted. (B) Replacing endogenous p31comet by p31comet-ΔC greatly delays exit from G2/M. HeLaK cells transfected to replace endogenous p31comet by the indicated FLAG3-Tev2–tagged variants were synchronously released from an RO-336–mediated G2 arrest and analyzed by time-resolved immunoblotting (Supplemental Figure 5B) and flow cytometry. (C) p31comet-ΔC is unable to support Trip13-dependent disassembly of Mad2-containing complexes. HeLaK cells containing the indicated siRNAs were transfected to express FLAG3-Tev2–tagged p31comet-WT or -ΔC or left untreated. Following their release from a G2 arrest, cells were subjected to time-resolved immunoblotting either directly (upper panels, “input”) or following Mad2-IP (lower panels). Note that Trip13 association with Mad2 is delayed but still occurs in the absence of p31comet; this association is reduced in the presence of p31comet-ΔC. (D) p31comet-ΔC is compromised in Rev7 and tp53 binding. HeLaK cells transiently transfected to express Myc6-Rev7 and FLAG3-Tev2–tagged p31comet-WT or -ΔC were treated for 2 hours with doxorubicin (DRB) or carrier solvent (-) and then subjected to IP-Western analyses using the indicated antibodies. Note that the interaction among p31comet, Rev7, and tp53 is strongly induced by infliction of DSBs. Note also that Rev7 interacts with Mad2 in undamaged cells, which is consistent with a previous report (65). γH2AX, S139-phosphorylated histone H2AX (marker for DSBs).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts